Elevating Analytical & CMC Proficiency to Ensure Novel & Complex Oligonucleotide Quality

Companies in the Room Include:

Welcome to the 3rd Oligonucleotide CMC & Analytical Development Summit

Accelerate Scalability & Regulatory Approvals for Novel, Complex Oligos with Product Quality & Cost-Efficiency to Achieve GMP Manufacturing 

This year we are witnessing continued growth and excitement of oligonucleotides, and most recently the $45m agreement between Eli Lilly and QurAlis to license ASO. Analytical Development, CMC and QC teams are under unprecedented pressure to enable clinical programming and commercialization without compromising on product quality and reducing cost of goods.

Much like any other emerging technologies and modalities, increasing oligonucleotide complexity without standard guidance can be a potential hurdle for the industry. This is why we are building this community to unite over 100 AD, QC, and CMC leaders working in the oligo field to share best practices, and together as a collective, seek solutions and standardized approaches to ensure robust testing, reproducible data and accelerate process intensification for scalability.

Join the likes of Ionis Pharmaceuticals, AstraZeneca, CAMP4 Therapeutics, Amgen and QurAlis at the 3rd Oligonucleotides CMC & Analytical Development Summit this August as we showcase brand-new content, data-driven case studies and exclusive networking opportunities. This is your definitive meeting to engage in meaningful dialogues with pioneering platform providers, to achieve GMP manufacturing of oligos at speed, and quality.


Oligo CMC brochure

Bringing together siRNA, ASO, and oligo-conjugate case studies, you will hear how to bring R&D analytical tools into the GMP setting

Leverage analytical data to improve process development and filing package

Mitigate risks of impurity during scale-up and tech transfer

Advance late-stage development alongside QC, validation and regulatory affairs team

World-Class Speaker Faculty Includes:

“I appreciated that there were many networking opportunities, and the participants were open to networking”

Molly Grun, Injectable Drug Product Development Scientist, Alexion Pharmaceuticals

“Highly informative & well-planned conference. This helped entire industries to share the good practice"

Haripada Maity, Chief Development Officer & Head of Biosimilars, Cipla

“It is a good opportunity to check the thought of experts in oligonucleotide CMC and AD. I really enjoyed the opportunity to catch up with old friends and meet new friends”

Bing Guan, Associate Director, IVERIC Bio

"I'm looking forward to socializing and networking with SMEs in the oligo field, sharing thought processes, strategies and future perspective"

Bao Cai, Executive Director, Process Development, Sarepta Therapeutics

2024 Partners

WuXi TIDES LOGO-blue version
ChemGenes_Logo_Blue (1)

Other Events in the Series